EORTC Leukemia Group Trials on Acute Myeloid Leukemias: An Overview

  • M. Hayat
  • R. Zittoun
  • P. Strychmans
  • B. Löwenberg
  • G. Solbu
  • S. Suciu
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)

Abstract

Originally designated as the Leukemia and Hematosarcoma Group, the EORTC Leukemia Group is one of the oldest of cooperative groups. It was created by Prof. G. Mathe in 1964 and been chaired since then by: G. Marchal (France), J. Bousser (France), W. F. Stenfert-Kroese (Netherlands), J. S. Malpas (United Kingdom), J. Bernard (France), H. O. Klein (Federal Republic of Germany), J. Revol (France), C. Hannen (Netherlands), P. Strychmans (Belgium), and R. Zittoun (France). This group has focused its efforts on the treatment of acute myeloid leukemia (AML). The objective of the present chapter is to present an overview of the trials hitherto conducted and the policy adopted for the ongoing trials on AML.

Keywords

Toxicity Hepatitis Leukemia Doxorubicin Methotrexate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Champlin R, Jacobs A, Gale RP (1984) Prolonged survival in acute myelogenous leukemia without maintenance chemotherapy. Lancet 1: 894–899PubMedCrossRefGoogle Scholar
  2. 2.
    Foon KA, Zighelboim J, Yale C, Gale RP (1981) Intensive chemotherapy in the treatment of choice for elderly patients with acute myelogenous leukemia. Blood 58: 467–470PubMedGoogle Scholar
  3. 3.
    Hayat M, Jehn U, Willemze R, Haanen C, Zittoun R, Monconduit M, Lowenberg B, Stryckmans P, Peetermans M, De Cataldo F, Kerkhofs H, Abels J, Klein HO, Andrien J, Goudsmit R, Cauchie C, Suciu S, Solbu G (1986) A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. Cancer 58: 617–623PubMedCrossRefGoogle Scholar
  4. 4.
    Jehn U, Suciu S, Hayat M, Zittoun R, Solbu G, Stryckmans P (1987) Testing a predictive regression model for response in adult acute myeloid leukemia comparing two induction regimens of the E.O.R.T.C. AML-5 and AML-6 trial. Anticancer Res 7: 1239–1244PubMedGoogle Scholar
  5. 5.
    Leukaemia and Hematosarcoma Cooperative Group of the E.O.R.T.C. (1973) A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia. Biomedicine (Paris) 18: 192–198Google Scholar
  6. 6.
    Leukaemia and Haematosarcoma Cooperative Group of the E.O.R.T.C. (1974) A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and danorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia. Eur J Cancer 10: 413–418Google Scholar
  7. 7.
    Lister TA, Whitehouse JMA, Oliver RID et al. (1980) Chemotherapy and immunotherapy for acute myelogenous leukemia. Cancer 46: 2142–2148PubMedCrossRefGoogle Scholar
  8. 8.
    Vogler WR et al. (1984) A randomized comparison of post remission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group Trial. Blood 63: 1039–1045PubMedGoogle Scholar
  9. 9.
    Zittoun R, Cadiou M, Bayle C, Suciu S, Solbu G, Hayat M and the E.O.R.T.C. Leukaemia and Hematosarcoma Cooperative Group (1984) Prognostic value of cytologic parameters in acute myelogenous leukemia. Cancer 53: 1526–1532Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • M. Hayat
    • 1
  • R. Zittoun
  • P. Strychmans
  • B. Löwenberg
  • G. Solbu
  • S. Suciu
  1. 1.Dept. of MedicineInstitute Gustave RoussyVillejuifFrance

Personalised recommendations